Grail, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
GRAL
Grail, INCGRAIL reports increased Galleri sales and reduced net losses in 2025, but faces challenges with a missed primary endpoint in the NHS-Galleri Trial and ongoing regulatory hurdles for broad reimbursement.
NASDAQ
GRAL
Grail, INCGRAIL, Inc. aims to revolutionize early cancer detection with its Galleri test, targeting FDA approval in 2026 and expanding commercial partnerships.